Denali Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Denali Therapeutics (DNLI).

Price Target Range — 12 Quarters

Analyst Consensus — 19 Analysts

18Buy

1Hold

Consensus RatingBuy# Analysts19Avg. Consensus PT$35Upside to Avg. PT+86.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 25, 2026	B. Riley Securities	Mayank Mamtani	PT Raise	Buy	$30→$35
Aug 7, 2026	UBS	Michael Yee	PT Raise	Buy	$25→$34
Jul 23, 2026	Morgan Stanley	Matthew Harrison	PT Raise	Overweight	$35→$36
Jul 16, 2026	Deutsche Bank	David Hoang	PT Raise	Buy	$31→$35
Jul 13, 2026	JP Morgan	Jessica Fye	Reinstates	Overweight	$29
May 26, 2026	Morgan Stanley	Matthew Harrison	PT Cut	Overweight	$40→$35
May 14, 2026	Morgan Stanley	Matthew Harrison	PT Cut	Overweight	$42→$40
May 11, 2026	BTIG	Thomas Shrader	Maintained	Buy	$39
May 8, 2026	Wedbush	Laura Chico	PT Cut	Outperform	$25→$23
Apr 22, 2026	Leerink Partners	Marc Goodman	PT Cut	Outperform	$40→$35
Apr 7, 2026	Baird	Joel Beatty	PT Raise	Outperform	$32→$34
Mar 26, 2026	Morgan Stanley	Matthew Harrison	PT Raise	Overweight	$40→$42
Mar 26, 2026	Goldman Sachs	Salveen Richter	PT Raise	Buy	$35→$40
Mar 26, 2026	Stifel	Paul Mattels	PT Raise	Buy	$34→$41
Mar 26, 2026	Baird	Joel Beatty	PT Raise	Outperform	$29→$32
Mar 26, 2026	HC Wainwright & Co.	Andrew S. Fein	PT Raise	Buy	$32→$42
Mar 25, 2026	BTIG	Thomas Shrader	PT Raise	Buy	$36→$38
Mar 2, 2026	BTIG	Thomas Shrader	PT Raise	Buy	$32→$36
Feb 24, 2026	Wolfe Research	Rudy Li	Initiate	Peer Perform	—
Feb 6, 2026	BTIG	Thomas Shrader	Maintained	Buy	$32

Analyst Ratings News

PRO
B. Riley Securities Maintains Buy on Denali Therapeutics, Raises Price Target to $35

B. Riley Securities analyst Mayank Mamtani maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the price target from $30 to $35.

Benzinga Newsdesk

PRO
UBS Maintains Buy on Denali Therapeutics, Raises Price Target to $34

UBS analyst Michael Yee maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the price target from $25 to $34.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Denali Therapeutics, Raises Price Target to $36

Morgan Stanley analyst Matthew Harrison maintains Denali Therapeutics (NASDAQ:DNLI) with a Overweight and raises the price target from $35 to $36.

Benzinga Newsdesk

PRO
Deutsche Bank Maintains Buy on Denali Therapeutics, Raises Price Target to $35

Deutsche Bank analyst David Hoang maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the price target from $31 to $35.

Benzinga Newsdesk

PRO
JP Morgan Reinstates Overweight on Denali Therapeutics, Announces $29 Price Target

JP Morgan analyst Jessica Fye reinstates Denali Therapeutics (NASDAQ:DNLI) with a Overweight and announces $29 price target.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Denali Therapeutics, Lowers Price Target to $35

Morgan Stanley analyst Matthew Harrison maintains Denali Therapeutics (NASDAQ:DNLI) with a Overweight and lowers the price target from $40 to $35.

Benzinga Newsdesk

Denali Therapeutics Inc

Denali Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
B. Riley Securities Maintains Buy on Denali Therapeutics, Raises Price Target to $35

PRO
UBS Maintains Buy on Denali Therapeutics, Raises Price Target to $34

PRO
Morgan Stanley Maintains Overweight on Denali Therapeutics, Raises Price Target to $36

PRO
Deutsche Bank Maintains Buy on Denali Therapeutics, Raises Price Target to $35

PRO
JP Morgan Reinstates Overweight on Denali Therapeutics, Announces $29 Price Target

PRO
Morgan Stanley Maintains Overweight on Denali Therapeutics, Lowers Price Target to $35

People Also Watch

People Also Watch

Denali Therapeutics Inc

Denali Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROB. Riley Securities Maintains Buy on Denali Therapeutics, Raises Price Target to $35

PROUBS Maintains Buy on Denali Therapeutics, Raises Price Target to $34

PROMorgan Stanley Maintains Overweight on Denali Therapeutics, Raises Price Target to $36

PRODeutsche Bank Maintains Buy on Denali Therapeutics, Raises Price Target to $35

PROJP Morgan Reinstates Overweight on Denali Therapeutics, Announces $29 Price Target

PROMorgan Stanley Maintains Overweight on Denali Therapeutics, Lowers Price Target to $35

People Also Watch

People Also Watch

PRO
B. Riley Securities Maintains Buy on Denali Therapeutics, Raises Price Target to $35

PRO
UBS Maintains Buy on Denali Therapeutics, Raises Price Target to $34

PRO
Morgan Stanley Maintains Overweight on Denali Therapeutics, Raises Price Target to $36

PRO
Deutsche Bank Maintains Buy on Denali Therapeutics, Raises Price Target to $35

PRO
JP Morgan Reinstates Overweight on Denali Therapeutics, Announces $29 Price Target

PRO
Morgan Stanley Maintains Overweight on Denali Therapeutics, Lowers Price Target to $35